ABSCIENCES (EPA:AB) | WebDisclosure

Basculer en Français

9784	Companies
196006	Keywords
127065	Articles
104238	Press releases

Home
Companies
ABSCIENCES

BRIEF

published on 09/30/2024 at 08:34, 1 year 4 months ago

AB Science annonce une augmentation de capital de 5,0 millions d’euros

Augmentation De Capital Développement Clinique AB Science Masitinib Investisseurs Européens
BRIEF

published on 09/30/2024 at 08:34, 1 year 4 months ago

AB Science announces a capital increase of 5.0 million euros

Capital Increase Clinical Development AB Science Masitinib European Investors
PRESS RELEASE

published on 09/30/2024 at 08:29, 1 year 4 months ago

AB Science annonce une augmentation de capital de 5,0 millions d’euros
AB Science annonce avec succès une augmentation de capital de 5 millions d’euros par placement privé pour financer le développement clinique de AB8939

Placement Privé Augmentation De Capital Développement Clinique AB Science AB8939
BRIEF

published on 09/23/2024 at 17:56, 1 year 4 months ago

AB Science fait le point sur le développement du masitinib dans les formes progressives de sclérose en plaques

Sclérose En Plaques Traitement Masitinib ECTRIMS 2024 Neurodégénératif
BRIEF

published on 09/23/2024 at 17:56, 1 year 4 months ago

AB Science provides an update on the development of masitinib in progressive forms of multiple sclerosis

Multiple Sclerosis Treatment Masitinib ECTRIMS 2024 Neurodegenerative
PRESS RELEASE

published on 09/23/2024 at 17:51, 1 year 4 months ago

AB Science fait aujourd'hui le point sur le développement du masitinib dans les formes progressives de la sclérose en plaques suite à la conférence ECTRIMS 2024
AB Science fait le point sur le développement du masitinib dans les formes progressives de la sclérose en plaques après la conférence ECTRIMS 2024

Sclérose En Plaques AB Science Masitinib ECTRIMS 2024 Étude MAXIMS
PRESS RELEASE

published on 09/23/2024 at 17:51, 1 year 4 months ago

AB Science provides an update on the development of masitinib in progressive forms of multiple sclerosis post ECTRIMS 2024
AB Science provides an update on the development of masitinib in progressive forms of multiple sclerosis post ECTRIMS 2024, showing promising results in phase 2B/3 study AB07002

Phase 3 Study AB Science Masitinib ECTRIMS 2024 Progressive Multiple Sclerosis
BRIEF

published on 07/08/2024 at 08:01, 1 year 6 months ago

AB Science Announces Positive Results of Phase 2 Study for Masitinib in COVID-19

COVID-19 Clinical Trial Phase 2 Study AB Science Masitinib
BRIEF

published on 07/08/2024 at 08:01, 1 year 6 months ago

AB Science annonce les résultats positifs de l'étude de phase 2 sur le masitinib dans le traitement du COVID-19

Essai Clinique Étude De Phase 2 COVID 19 AB Science Masitinib
PRESS RELEASE

published on 07/08/2024 at 07:56, 1 year 6 months ago

AB Science announces positive results of its Phase 2 study evaluating masitinib in Covid-19
AB Science reports positive results of its phase 2 study evaluating masitinib in COVID-19, showing improved clinical status in hospitalized patients. Study indicates potential for masitinib as a COVID-19 treatment

COVID-19 Treatment Phase 2 Study AB Science Masitinib

Accesswire

Published on 02/02/2026 at 23:55, 3 hours 49 minutes ago

2026 Tunkillia Development Drilling Programs Begin
Published on 02/02/2026 at 23:55, 3 hours 49 minutes ago

55 North Mining Announces Winter Exploration Drill Program at Last Hope Gold Project
Published on 02/02/2026 at 23:25, 4 hours 19 minutes ago

Western Announces Sale of GlassMasters Investment
Published on 02/02/2026 at 22:05, 5 hours 39 minutes ago

Organto Foods to Attend Fruit Logistica 2026 in Berlin, Germany From February 4-6, 2026
Published on 02/02/2026 at 15:00, 12 hours 44 minutes ago

Jericho Energy Ventures Strategically Terminates SmartKem LOI to Advance Independent Data Center Energy Infrastructure Platform

View all ACCESSWIRE

EQS Group

Published on 02/02/2026 at 20:00, 7 hours 43 minutes ago

CGTN AMERICA & CCTV UN: Cultural Event Celebrating the Spring Festival and the 55th Anniversary of China-U.S. Ping-Pong Diplomacy
Published on 02/02/2026 at 19:57, 7 hours 46 minutes ago

US federal court grants preliminary injunction allowing Sunrise Wind construction to resume
Published on 02/02/2026 at 19:42, 8 hours 1 minute ago

EQS-Adhoc: ProSiebenSat.1 publishes preliminary figures for financial year 2025
Published on 02/02/2026 at 19:05, 8 hours 38 minutes ago

Virtual Science AI launches the life science industry's first medical congress AI solution for real-time event conversational intelligence
Published on 02/02/2026 at 19:00, 8 hours 43 minutes ago

PATRIMOINE ET COMMERCE: INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET AU NOMBRE D’ACTIONS COMPOSANT LE CAPITAL SOCIAL AU TITRE DE L’ARTICLE 223-16 DU REGLEMENT GENERAL DE L'AMF

Les Echos

Published on 02/02/2026 at 18:23, 9 hours 20 minutes ago

Monthly disclosure of the total number of shares and voting rights - January 2026
Published on 02/02/2026 at 18:23, 9 hours 20 minutes ago

TF1 - Déclaration mensuelle des actions et droits de vote - Janvier 2026
Published on 02/02/2026 at 18:00, 9 hours 44 minutes ago

Covivio - Information on total number of voting rights and share capital
Published on 02/02/2026 at 18:00, 9 hours 44 minutes ago

Covivio Hotels - Informations relatives au nombre total de droits de vote et d’actions composant le capital social
Published on 02/02/2026 at 18:00, 9 hours 44 minutes ago

Covivio - Informations relatives au nombre total de droits de vote et d’actions composant le capital social

View all LES ECHOS COMFI WIRE